Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics

Scott A McConnell,1 Dharmik N Desai,1 Sejal P Faldu,1 Marjie L Hard,2 Angela Y Wehr,3 Peter J Weiden,1 Lisa von Moltke3 1Medical Affairs, Alkermes, Inc., Waltham, MA, 2Nuventra Pharma Sciences, Durham, NC, 3Clinical Research, Alkermes, Inc., Waltham, MA, USAThe recent publication by Salzman et al1...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	McConnell SA, Desai DN, Faldu SP, Hard ML, Wehr AY, Weiden PJ, von Moltke L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	aripiprazole aripiprazole lauroxil pharmacokinetics;long-acting injectables Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/8036fa34f015403b9c1b841a7c733a17
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8036fa34f015403b9c1b841a7c733a17
record_format	dspace
spelling	oai:doaj.org-article:8036fa34f015403b9c1b841a7c733a172021-12-02T04:23:19ZLong-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics1178-2021https://doaj.org/article/8036fa34f015403b9c1b841a7c733a172017-07-01T00:00:00Zhttps://www.dovepress.com/long-acting-formulations-delivering-aripiprazole-beyond-single-value-c-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Scott A McConnell,1 Dharmik N Desai,1 Sejal P Faldu,1 Marjie L Hard,2 Angela Y Wehr,3 Peter J Weiden,1 Lisa von Moltke3 1Medical Affairs, Alkermes, Inc., Waltham, MA, 2Nuventra Pharma Sciences, Durham, NC, 3Clinical Research, Alkermes, Inc., Waltham, MA, USAThe recent publication by Salzman et al1 compared pharmacokinetic (PK) data from population PK (popPK) models for two long-acting antipsychotic formulations: aripiprazole once-monthly 400 mg (AOM 400) and aripiprazole lauroxil (AL). We would like to address a few major concerns. The AL popPK model has been well described in a peer-reviewed publication.2 However, Salzman et al omitted publishing information regarding the development and validation of the AOM popPK model, including any critical discussion of the covariates, other key characteristics, assumptions and limitations of the AOM model. Thus, a reader cannot objectively assess the simulated values for AOM reported in the publication.View the original paper by Salzman and colleagues.McConnell SADesai DNFaldu SPHard MLWehr AYWeiden PJvon Moltke LDove Medical Pressarticlearipiprazolearipiprazole lauroxilpharmacokinetics;long-acting injectablesNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 1815-1816 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	aripiprazole aripiprazole lauroxil pharmacokinetics;long-acting injectables Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	aripiprazole aripiprazole lauroxil pharmacokinetics;long-acting injectables Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 McConnell SA Desai DN Faldu SP Hard ML Wehr AY Weiden PJ von Moltke L Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics
description	Scott A McConnell,1 Dharmik N Desai,1 Sejal P Faldu,1 Marjie L Hard,2 Angela Y Wehr,3 Peter J Weiden,1 Lisa von Moltke3 1Medical Affairs, Alkermes, Inc., Waltham, MA, 2Nuventra Pharma Sciences, Durham, NC, 3Clinical Research, Alkermes, Inc., Waltham, MA, USAThe recent publication by Salzman et al1 compared pharmacokinetic (PK) data from population PK (popPK) models for two long-acting antipsychotic formulations: aripiprazole once-monthly 400 mg (AOM 400) and aripiprazole lauroxil (AL). We would like to address a few major concerns. The AL popPK model has been well described in a peer-reviewed publication.2 However, Salzman et al omitted publishing information regarding the development and validation of the AOM popPK model, including any critical discussion of the covariates, other key characteristics, assumptions and limitations of the AOM model. Thus, a reader cannot objectively assess the simulated values for AOM reported in the publication.View the original paper by Salzman and colleagues.
format	article
author	McConnell SA Desai DN Faldu SP Hard ML Wehr AY Weiden PJ von Moltke L
author_facet	McConnell SA Desai DN Faldu SP Hard ML Wehr AY Weiden PJ von Moltke L
author_sort	McConnell SA
title	Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics
title_short	Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics
title_full	Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics
title_fullStr	Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics
title_full_unstemmed	Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics
title_sort	long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/8036fa34f015403b9c1b841a7c733a17
work_keys_str_mv	AT mcconnellsa longactingformulationsdeliveringaripiprazolebeyondsinglevaluecharacterizationsofsteadystatepharmacokinetics AT desaidn longactingformulationsdeliveringaripiprazolebeyondsinglevaluecharacterizationsofsteadystatepharmacokinetics AT faldusp longactingformulationsdeliveringaripiprazolebeyondsinglevaluecharacterizationsofsteadystatepharmacokinetics AT hardml longactingformulationsdeliveringaripiprazolebeyondsinglevaluecharacterizationsofsteadystatepharmacokinetics AT wehray longactingformulationsdeliveringaripiprazolebeyondsinglevaluecharacterizationsofsteadystatepharmacokinetics AT weidenpj longactingformulationsdeliveringaripiprazolebeyondsinglevaluecharacterizationsofsteadystatepharmacokinetics AT vonmoltkel longactingformulationsdeliveringaripiprazolebeyondsinglevaluecharacterizationsofsteadystatepharmacokinetics
_version_	1718401256863563776

Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics

Ejemplares similares